Cost and Utilization Outcomes of Pharmacist-Led Medication Therapy Optimization in a Medicare ACO Population

Clicks: 51
ID: 326546
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #7 of 168 articles by views in Health Affairs Scholar

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 168 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Medication-related problems are a persistent source of avoidable spending among Medicare beneficiaries, presenting an important opportunity to improve the quality of care for seniors and reduce financial burden on the Medicare program. Methods We evaluated a pharmacist-led medication therapy optimization (MTO) program implemented in a Medicare accountable care organization population using a regression-adjusted difference-in-differences design with propensity score matching. The analysis included 1,003 treated members and 14,031 matched controls contributing 334,531 member-months of claims data (2022–2025). The MTO program combined pharmacogenomic testing, a nine-vector medication-risk algorithm, comprehensive pharmacist review, and structured recommendations to prescribers. Results MTO participation was associated with a statistically significant reduction in total medical costs (pooled average treatment effect on the treated: −19.4%, −$246 per member per month [PMPM]; p<0.001). The treatment effect was strongly duration-dependent, growing from −4.7% in the first three months to −31.9% (−$462 PMPM; p<0.001) beyond nine months of program benefit. All care settings showed significant reductions: inpatient admissions −43.1% (p<0.001), emergency department visits −41.3% (p<0.001), and outpatient visits −28.3% (p<0.001). Conclusion Parallel trends validation and a pronounced dose-response relationship support a causal interpretation. Short-duration evaluations are likely to substantially underestimate the full economic value of an MTO program.
Reference Key
openalex_W7204273652 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hazem Elewa, Joseph Levy, Chintan Pandya, Steven E. Goldberg, Travis A Morgan
Are you one of these authors? Claim your profile
Journal Health Affairs Scholar
Year 2026
DOI
10.1093/haschl/qxag223
URL
https://doi.org/10.1093/haschl/qxag223
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.